MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
MindMed, a clinical stage biopharmaceutical company, will host a conference call on May 8, 2024, to discuss first quarter financial results. The company is focused on developing novel treatments for brain health disorders.
- None.
- None.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, https://ir.mindmed.co/, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240502898236/en/
For Media: media@mindmed.co
For Investors: ir@mindmed.co
Source: MindMed
FAQ
When will MindMed host a conference call to discuss first quarter 2024 financial results?
What is MindMed's stock symbol?
What does MindMed focus on?
Where can listeners register for the webcast?